Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Price Target at $3.67

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have earned an average recommendation of “Hold” from the five research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $3.67.

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Piper Sandler dropped their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Leerink Partnrs lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. StockNews.com assumed coverage on Lexicon Pharmaceuticals in a report on Saturday. They issued a “sell” rating on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd.

Lexicon Pharmaceuticals Trading Down 5.5 %

Shares of NASDAQ:LXRX opened at $0.42 on Tuesday. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45. The company has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.96. The stock has a market capitalization of $103.15 million, a price-to-earnings ratio of -0.56 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. On average, research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its stake in shares of Lexicon Pharmaceuticals by 29.9% in the fourth quarter. California State Teachers Retirement System now owns 195,215 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 44,915 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Lexicon Pharmaceuticals by 193.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 353,508 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 233,121 shares in the last quarter. Tang Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals by 750.3% during the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 750,268 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Lexicon Pharmaceuticals by 630.7% during the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after purchasing an additional 7,758,371 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of Lexicon Pharmaceuticals by 378.0% in the fourth quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 249,616 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.